Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

This publication has 11 references indexed in Scilit:

• Cediranib Plus FOLFOX/CAPOX Versus Placebo Plus FOLFOX/CAPOX in Patients With Previously Untreated Metastatic Colorectal Cancer: A Randomized, Double-Blind, Phase III Study (HORIZON II)
  Journal of Clinical Oncology, 2012
• Cediranib With mFOLFOX6 Versus Bevacizumab With mFOLFOX6 As First-Line Treatment for Patients With Advanced Colorectal Cancer: A Double-Blind, Randomized Phase III Study (HORIZON III)
  Journal of Clinical Oncology, 2012
• Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study
  British Journal of Cancer, 2012
• An Update on the Current and Emerging Targeted Agents in Metastatic Colorectal Cancer
  Clinical Colorectal Cancer, 2011
• Randomized, Placebo-Controlled, Phase III Study of Oxaliplatin, Fluorouracil, and Leucovorin With or Without PTK787/ZK 222584 in Patients With Previously Treated Metastatic Colorectal Adenocarcinoma
  Journal of Clinical Oncology, 2011
• Randomized, Placebo-Controlled, Phase III Study of First-Line Oxaliplatin-Based Chemotherapy Plus PTK787/ZK 222584, an Oral Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Metastatic Colorectal Adenocarcinoma
  Journal of Clinical Oncology, 2011
• Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
  International Journal of Cancer, 2010
• Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment
  Annals of Oncology, 2010
• Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer
  Health and Quality of Life Outcomes, 2007
• Interpreting the significance of changes in health-related quality-of-life scores.
  Journal of Clinical Oncology, 1998